Bernard A. Fox, Co – founder, President, and CEO of UbiVac, shared OncoDaily’s post on LinkedIn, adding:
“WHAT A GREAT CHOICE!
Dr. Steven O’Day has been at the forefront of immunotherapy for patients with melanoma since the beginning. His presentation of the initial positive clinical results of the Medarex / Bristol Myers Squibb anti-CTLA-4 / Ipilimumab in patients with melanoma at ASCO 2010 opened a new era in cancer treatment.
Looking forward to the OncoDaily program on World Melanoma Day 2026.
Will note that Dr. O’Day is leading clinical development of a promising nextgen anti-CTLA4 at Agenus. Early clinical data shows activity in cancers with unmet need. Great to see Dr. O’Day Keeping up the fight to finish cancer
Also – thanks to the diehard believers who made the clinical application of anti-ctla-4 possible.. James Allison, Nils Lonberg, Alan Korman and others.”
More posts featuring Bernard A. Fox.